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Summary Exacerbations of COPD have a profound detrimental effect on the pa-
tient and impose a significant burden on healthcare resource utilization. Preven-
tion and treatment of exacerbations are major objectives of the clinical manage-
ment of COPD. For this approach to be successful, clinicians must combine both
pharmacologic approaches and non-pharmacologic strategies aimed at improving
the patient' s disease management.
Non-pharmacologic approaches include those that can be incorporated into the of-
fice setting as well as intervention strategies that are integrated into the lifelong
management of COPD. These strategies include developing a partnership with the
patient and their social supports, encouraging and facilitating smoking cessation,
immunizations, proper use of supplemental oxygen, and most importantly, giving
the patient the tools to manage their illness appropriately. Moreover there is clear
evidence of an irrevocable decline in pulmonary function after each exacerbation,
usually resulting in reduced physical activity and impaired skeletal muscle func-
tion. Not surprisingly, pulmonary rehabilitation after such events has been shown
to prevent relapse, improve survival and enhance patients' overall function after
acute exacerbations.
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It is now accepted that during an exacerbation there is an increased inflammation
both in the lung and in the systemic circulation that can affect many organs and
systems, causing serious complications. Several classes of pharmacological agents
are currently available which have varying efficacy with regard to preventing ex-
acerbations. However, further knowledge is needed regarding the varying clinical
phenotypes of COPD and the mechanisms by which infections and other environ-
mental agents trigger exacerbations, so that ultimately, pharmacologic therapy
can be better targeted to provide specific patient benefits.
© 2008 Elsevier Ltd. All rights reserved.
Introduction
Exacerbations of COPD have a profound effect on
the patient, contributing significantly to the mor-
bidity and mortality of this disease. Patients with
frequent exacerbations have worse health-related
quality of life (HRQOL) than those who do not, which
may contribute to the association between impaired
HRQOL and mortality in COPD. Exacerbations also
impose a significant burden on healthcare resource
utilization. Prevention and treatment of exacerba-
tions are major objectives of the clinical manage-
ment of COPD and are prominently listed in both
the Global Initiative for Chronic Obstructive Lung
Disease (GOLD)3 and the ATS/ERS Standards for the
Diagnosis and Management of COPD4. Recognition
and management of the exacerbation is also a cor-
nerstone in self-management education programs in
COPD.5
There is no clear consensus as to the definition
of a COPD exacerbation. The definition proposed
in the GOLD document is a pragmatic consensus of
several existing definitions and defines an exacer-
bation as: a`n event in the natural course of the
disease characterized by a change in the patient' s
baseline dyspnea, cough and or sputum that is be-
yond normal day-to-day variations, is acute in onset
and may warrant a change in regular medication' 3.
The definition does not include the notion that
other events may mimic or complicate an exacer-
bation such as congestive heart failure, pneumo-
nia or pneumothorax6 (see Figure 1). Risk factors
for severe exacerbations (requiring hospital admis-
sion) include recent discharge after a COPD hospi-
talization, advanced age, low baseline lung func-
tion, prior systemic corticosteroid use, low body
mass index (BMI), the presence of co-morbidities,
underutilization of home oxygen and poor quality
of life7,8. Poor physical activity levels may also pre-
dispose patients to readmission after a severe ex-
acerbation or may even facilitate a first hospital
admission9. Exacerbations are often associated with
worsening airflow obstruction and can result in a
more rapid decline of lung function,8 increased pe-
ripheral muscle weakness,10 decreased quality of
Figure 1
life,1 increased health care costs,11,12 and increased
mortality.13 It is now accepted that during an exac-
erbation there is an increased inflammation both in
the lung and in the systemic circulation that can af-
fect many organs and systems, causing serious com-
plications. As a consequence, numerous abnormal-
ities can be found outside the lung, mainly affect-
ing the nutritional status, skeletal muscle function,
bone tissue mass, and cardiovascular, endocrine and
other systems.
It has been demonstrated that early therapy
speeds exacerbation recovery,14 and reduces health
care utilization15 and therefore, early recognition
and treatment of exacerbations has enormous po-
tential to change and modify the course of disease.
For this approach to be successful, clinicians must
combine both a pharmacologic approach to preven-
tion and treatment, as well as strategies aimed at
behavior modification in order to improve patient
confidence in their ability to make life-improving
changes.
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Systemic consequences of COPD
exacerbations
An increase in the levels of markers of inflamma-
tion has been found in bronchial secretions in pa-
tients with an acute exacerbation. For example,
Saetta et al.16 demonstrated an increase of air-
way eosinophils, later confirmed in the work of Zhu
et al17. Tsoumakidou et al.18 found an imbalance
in T-lymphocyte subpopulations at the onset of se-
vere exacerbations whilst Fiorini et al.19 showed
increased serum eosinophil chemotactic factor and
myeloperoxidase during acute exacerbations. At ex-
acerbation, a close relationship has also been found
between the inflammation of the respiratory tract
and systemic inflammation, with the degree of sys-
temic inflammation related to inflammation of the
lower and upper airways20. This allows the moni-
toring of the time-course of the lung inflammatory
process through the changes of systemic markers21.
All these findings demonstrate that during an ex-
acerbation of COPD an increased inflammatory pro-
cess takes place both in the lung and in the sys-
temic circulation, which can have dramatic effects
on the structure and function of various organs and
systems.
Roland et al.22 were able to show that endothe-
lin (ET)-1, a potent vasoconstrictive peptide mainly
produced by the bronchial epithelium and impli-
cated in the pathogenesis of asthma, may also play
a role in COPD exacerbations. This peptide was sig-
nificantly increased during exacerbations compared
to the stable state and can be considered a marker
of disease severity both during stability and exacer-
bation, because its serum level was negatively cor-
related with the baseline values of FEV1 and with
the change of oxygen saturation during the exacer-
bation. Hurst et al23 assessed the utility of plasma
biomarkers to confirm an exacerbation and to pre-
dict its severity by evaluating 36 biomarkers in 90
paired baseline and exacerbation plasma samples
from 90 patients with COPD. CRP was the most se-
lective marker in order to confirm the diagnosis of
exacerbation, but it was not sensitive or specific
enough, while the combination of CRP with any one
of dyspnoea, sputum volume or sputum purulence
significantly improved its significance. In addition,
a possible relationship between the CRP value, as a
marker of systemic inflammation, and time to ex-
acerbation in patients with COPD has recently been
reported. Higher levels of stable state inflammation
seem to predispose to an earlier exacerbation,24 es-
pecially when the CRP value remains elevated two
weeks after an exacerbation episode25.
Leptin has also been demonstrated to increase in
peripheral blood during acute exacerbations which
possibly intervenes in the nutritional alterations and
systemic inflammation that characterize the acute
exacerbation26. The influence of acute exacerba-
tions on nutritional and metabolic status of patients
with COPD has been investigated by Vermeeren et
al.27 These authors studied 23 consecutive patients
at hospital admission for an acute exacerbation,
at discharge, and at three months after discharge.
They found that the calculated dietary intake prior
to admission was significantly lower than the ha-
bitual one; it increased during hospitalisation and
at discharge was greater than the habitual, return-
ing to almost normal after three months. On the
contrary, resting energy expenditure (REE) was ele-
vated on admission which significantly decreased af-
ter the fourth day of hospitalisation and was signifi-
cantly correlated with the sensation of dyspnoea. In
a subgroup of patients REE, remained higher than in
the other patients as a marker of persisting hyper-
metabolism. Patients showing these metabolic char-
acteristics presented a significantly lower BMI com-
pared to those with a normal metabolism. The in-
creased REE on admission was paralleled by a neg-
ative energy balance which was restored with ther-
apy for the exacerbation. The acute exacerbation in
this study induced in the majority of patients a de-
crease in the dietary intake, especially of fat, due to
the dyspnoea and fatigue during eating. The raised
REE in patients with exacerbations of COPD has been
related to an increase in work of breathing, to drugs
used for the exacerbation, especially beta-2 ago-
nists and systemic inflammation27. The increased
REE during the acute exacerbation, together with
the increased systemic inflammation and hypoxia,
may potentially worsen the damage of respiratory
and skeletal muscles and further impair their func-
tionality.
This confirms that during an exacerbation both
in the lung and in the systemic circulation there is
an increased inflammation that can worsen the al-
terations affecting various structures and functions.
Thus, adequate prevention and treatment of acute
exacerbations represents a critical target to achieve
in the treatment of COPD.
Integrating exacerbation prevention strategies
into clinical COPD management
Several strategies can be applied in order to prevent
exacerbations. For clinicians it is of utmost impor-
tance to prevent relapse after an exacerbation. As
mentioned previously, having had an exacerbation is
the most important risk factor for consecutive exac-
erbations. Hence interventions to prevent exacerba-
tions should be primarily targeted to those patients
who have already suffered from an exacerbation.
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Non-pharmacologic approaches
Smoking cessation
Cigarette smoking is the single most important
cause of COPD as well as a major risk factor for
many other diseases including atherosclerotic vas-
cular disease and cancer. Smokers have an accel-
erated decline in lung function and smoking cessa-
tion can slow the progressive loss of lung function
and reduce symptoms28. Studies have not yet ad-
dressed the effect of smoking cessation on exac-
erbation frequency, which is likely due to the fact
that most patients enrolled in such cessation pro-
grams are at an earlier stage of COPD when exac-
erbations are less frequent. However, since smoking
cessation decreases cough and sputum production
which are important predictors of exacerbation,29 it
is highly likely that this intervention will reduce the
risk of frequent exacerbations. It has been shown
that smoking cessation enhances survival30. In this
study the death rates from respiratory diseases un-
related to lung cancer was twofold higher in the
usual care group compared to the special interven-
tion (smoking cessation) group. Although this was
not formally linked to an exacerbation it is highly
suggestive of a higher prevalence of exacerbations
in a group of patients not submitted to a smoking
cessation program.
Immunizations
Vaccination against influenza is a highly cost-
effective intervention to reduce the number of
COPD exacerbations. In a study of 1,898 elderly pa-
tients with chronic lung disease, influenza immu-
nization virtually eliminated excess risk of hospital-
ization and death due to the virus31. One random-
ized trial in the UK showed that influenza vaccina-
tion reduced total COPD exacerbations by 50% over
the winter months32. Immunized patients also ap-
pear to have fewer outpatient visits for respiratory
complaints.
Pneumococcal vaccine may also have some pro-
tective effect against severe COPD exacerbations33.
In the same retrospective study of 1,898 elderly pa-
tients mentioned above, the benefits of both in-
fluenza and pneumococcal vaccines were additive
with fewer hospitalizations for pneumonia. Pneumo-
coccal vaccination was also associated with reduced
health care costs.
Oxygen
Long term oxygen therapy (LTOT) may also con-
tribute to fewer exacerbations in hypoxemic COPD
patients. For example, among 246 COPD patients
started on LTOT during a hospitalization or as out-
patients, there was a 24---44% reduction in hospital
admission and hospital days in the 10 months fol-
lowing initiation of oxygen therapy34.
Office practice interventions
Interventions aimed at decreasing the frequency of
COPD exacerbations must begin in the office set-
ting. Health care providers should develop a part-
nership with the patient and their social supports.
Questions such as “what activities are you doing?”
rather than “how are you doing?” may more accu-
rately reflect the current functional status of the
patient. As disease progresses and the likelihood of
exacerbation increases, more frequent contact be-
tween the patient and healthcare provider may be
indicated. Compliance with the medical regimen,
proper inhaler use and inquiries into potential rea-
sons for non-adherence are all important issues to
be addressed and re-addressed in the office setting.
In order to facilitate proper action by the patient
an action plan may be put in place. The patient
may be given a prescription for oral corticosteroid
treatment in case of exacerbation so that if patients
recognize their exacerbation they may use this pre-
scription in order to tackle the first symptoms of an
exacerbation as soon as possible.15 Such an inter-
vention should be embedded in a program aiming at
enhancing self management and patient education
(see below).
Patient self-management education
Patient self-management education is an essential
component in the care of patients with COPD. The
goals of these self-management strategies are to en-
hance coping skills, foster a sense of well-being and
improve patient' s self-efficacy (confidence in their
ability to make life-improving changes) and adher-
ence. Exacerbation prevention is a topic of major
concern to both the patient and the clinician. “Ac-
tion plans” that address important aspects of exac-
erbation prevention are best designed by the health
care provider in partnership with the patient in a
mutually respectful and trusting relationship. The
action plan should reflect the individual patient' s
experience of an acute exacerbation15. Behaviour
change, however, does not occur without significant
effort on the part of both patient and clinician. The
acquisition of a new behaviour will require contin-
uous reinforcement and maintenance of behaviour
over time will require intermittent reinforcement.
The benefits of self-management education are
shown in two randomized clinical trials35,36. The
Targeting the COPD Exacerbation S7
study that focussed on patients who suffered
from a recent exacerbation clearly showed short,
medium15 and long term37 benefits at an affordable
cost38. However, larger and more sensitively de-
signed studies need to be done to fully capture the
effectiveness of self-management education. Ques-
tions remain as to precisely how much patient ben-
efit is afforded by this strategy, how to identify
which patients will benefit the most and whether
or not the economic costs justify the clinical bene-
fits. In addition, it will be important to determine
which self-management strategies result in long-
term maintenance of health behaviour change. Ide-
ally these programs are embedded in a more general
rehabilitation program (see below).
Community-based management of exacerbations
A number of nurse-led home-care initiatives have
shown early success in the management of COPD
exacerbations. Since these programs generally re-
quire some logistical effort these programs should
be directed primarily to patients with recent hos-
pital admissions. Farrero et al39 followed COPD
patients receiving long-term oxygen therapy with
weekly phone calls and 3 home visits, providing
easy access to and quick response from clinicians
who were involved in their continuing care. The
use of a case manager familiar with the patient
offered expert care at an early stage of the exac-
erbation resulted in a 70% reduction of emergency
department visits and a 60% reduction in hospital
admissions. Other community-based modalities in
preventing exacerbations are also currently being
studied. Hernandez40 is examining the effect of pa-
tient self-monitoring of symptoms, daily spirome-
try and pulse oximetry (using a hand-held wireless
device) on exacerbations among 80 clinically stable
COPD patients. This device and frequent collabora-
tion with the nurse case manager has been helpful
in the development of behavioural strategies to im-
prove adherence. Further studies need to be done to
confirm the cost benefits of home-based programs
and technologies in preventing exacerbations.
Pulmonary Rehabilitation immediately following
the COPD exacerbation
Pulmonary rehabilitation (PR) has been unequiv-
ocally shown to improve exercise tolerance and
HRQOL41. Most studies have focused on PR in stable
COPD patients, however PR after the acute exac-
erbation may also merit attention. The goals of PR
after acute exacerbation include:
(1) Prevention of new exacerbations
(2) Reduction in severity of the exacerbation
(3) Restoration of pre-exacerbation functional sta-
tus
(4) Resumption of a realistic amount of physical ac-
tivities of daily life.
These goals may be achieved through enhance-
ment of physiological function (increased skeletal
muscle strength and endurance, exercise tolerance
and mechanical efficiency). Achieving these goals
would then allow patients to engage in progressive
exercise and in a more active life style. Increased
self management skills would allow the patient to
recognize exacerbations early and permit them to
act appropriately to prevent severe exacerbations
from occurring36. The enhanced self efficacy ob-
served after PR may also help the patient to over-
come the barriers to a physically active life style42.
From a meta-analysis performed on the limited
data available, a consistent pattern has emerged.
PR undertaken after a severe acute exacerbation,
improves HRQOL, enhances exercise tolerance, and
has a significant effect on hospital readmission and
all cause mortality rate43. A recent study, large
enough to address the benefits of PR established im-
mediately after an acute exacerbation, also showed
an impressive improvement in HRQOL (an improve-
ment which was three-fold the minimal clinically
important difference compared to usual care).44
Furthermore functional exercise tolerance was in-
creased substantially and the number of emergency
visits was substantially reduced (incidence ratio
0.14 compared to usual care) after this 8 week pro-
gramme. In the rehabilitation group 35% of the pa-
tients were readmitted, compared to 57% in the
usual care group.
Specific considerations for rehabilitation
during and after acute exacerbations of
COPD
Rehabilitation programs immediately following
acute exacerbations should be conducted carefully.
Patients with COPD, especially those suffering from
acute exacerbations may have comorbid conditions
that complicate regular exercise training. Conges-
tive heart failure45,46, deep venous thrombosis47
and pulmonary hypertension48 frequently occur in
combination with severe exacerbations. During the
acute phase of the exacerbation, increased oper-
ational lung volumes49 and anemia50 contribute to
the perception of symptoms and to the inactivity.
All the afore mentioned factors may make it dif-
ficult to set up regular exercise training at an in-
tensity or duration high enough to achieve benefi-
cial effects. Since bicycle exercise is slightly more
fatiguing compared to walking exercise at identi-
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cal oxygen consumption51, cycling may be the pre-
ferred form of whole body exercise in situations
where the ventilatory capacity is reduced. Patients,
however, may be unable to perform bouts of exer-
cise on a bicycle or treadmill at sufficient inten-
sity. However, alternative forms of exercise such
as resistance training52 and neuromuscular electri-
cal stimulation53,54 may be alternative strategies in
these more critical patients, especially in the early
phases of the exacerbation.
In patients who experience difficulties walking,
activities of daily living can be facilitated using
walking aids.55,56 Wheeled walking aids improve
walking efficiency and allow patients to rest when-
ever needed57 thereby enhancing patient confi-
dence that walking is a feasible endeavor.
No research conducted to date guides us regard-
ing the preferred format of PR after acute exac-
erbations. Surely, extending the hospital admission
to provide an inpatient PR program may result in
significant benefits58, but can be very costly and
may impose an unnecessary risk of prolonged hos-
pital admission on patients. Outpatient programs
seem to be a valid alternative44. Neuromuscular
electrical stimulation may be administered in the
home setting, as this intervention requires only min-
imal supervision54. One, relatively small study es-
tablished a home rehabilitation program immedi-
ately after discharge and found significant benefits
in terms of skeletal muscle strength, exercise tol-
erance and HRQOL. The home rehabilitation group
also tended to have fewer readmissions (p = 0.06).10
Another open question is when should PR be started.
Given the fact that skeletal muscle weakness occurs
rapidly59 and inactivity seems almost inevitable60,
stimulation of the peripheral muscles with exercise
training should not be postponed too long. It can be
reasoned, however, that due to increased inflamma-
tion and systemic oxidative stress, stimulating the
muscle too early during the exacerbation may be po-
tentially harmful. Preliminary data from Probst and
colleagues suggests that specific resistance train-
ing begun on the second day of a hospital admis-
sion is feasible and may prevent the decline in mus-
cle strength seen with usual care following COPD
exacerbations60.
Recent studies highlight the important benefits
obtained from streamlining the care of patients
during acute exacerbations. Aspects of PR can be
transferred to dedicated primary care health care
providers, but communication with more special-
ized centers appears crucial to prevent readmission
to the hospital after an acute exacerbation.61 In the
center where patients are admitted, care should be
structured such that patients have all the needed
pharmacological and non-pharmacological prescrip-
tions to continue care after the exacerbation. It is
clear that usual medical care alone does not restore
physical activity levels and specific attention should
be given to revalidation. The details as to when to
start formal rehabilitation and where to organize
the rehabilitation may be subject to further inves-
tigation and may depend on regional availability of
rehabilitation facilities.
Preventing the COPD exacerbation through
pharmacological interventions
The several classes of pharmacologic agents cur-
rently available for treatment of COPD have varying
efficacies with regard to preventing COPD exacer-
bations. The actual efficacy of any individual class
of agents is difficult to assess due to problems with
interpretation of data from existing clinical trials.
Such problems include variations across studies in
the definition of COPD exacerbation, criteria for the
diagnosis of COPD, clinical phenotypes and COPD
severity included in the studies, as well as varia-
tions in study design and statistical analysis meth-
ods. Nevertheless, in viewing the evidence with re-
gard to each class of agents as a whole, it is possible
to recognize strong trends that provide an estimate
of the range of efficacy in exacerbation prevention.
Bronchodilators, inhaled corticosteroids and combi-
nation therapy are the current mainstays of pharma-
cologic therapy with potential to reduce exacerba-
tions. Evidence is mounting that phosphodiesterase-
4 inhibitors are also helpful and immunomodulators
and mucolytics may prove beneficial for selected
patients.
Short-acting bronchodilators
On the whole, it is difficult to assess or prove the
impact of regular use of short-acting bronchodila-
tors on COPD exacerbations. This difficulty arises
from the fluctuation in symptoms often associated
with short-acting bronchodilator use, variability
in severity of respiratory symptoms and of use
of medications from one day to the next, and
variability in clinical study design. Nevertheless,
some data suggest that inclusion of ipratropium in
a regimen of short-acting bronchodilators can lower
exacerbation rates.62
Long-acting beta-agonists (LABA)
Most trials investigating the efficacy of the long-
acting beta-agonists, salmeterol and formoterol in
COPD have not chosen exacerbation rates or sever-
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ity as the primary outcome. However, across a large
number of studies, analysis has revealed that LABAs
reduce COPD exacerbations by approximately 20%.63
One recent systematic review examining the over-
all effects of LABA on multiple COPD outcomes re-
vealed that in comparison to placebo, regular use of
salmeterol had a favorable treatment effect on ex-
acerbation rates.63 The magnitude of this effect was
comparable across the different studies included in
the analysis. Similar results can be found for the ef-
fects of formoterol.63 Although long-term trials of
therapy with LABAs alone evaluating COPD exacer-
bations as a primary outcome are lacking, it is im-
portant to note that no studies have shown a lesser
effect of these agents on exacerbation rates as com-
pared to placebo or short-acting bronchodilators.
Moreover, the use of LABAs in COPD leads to im-
proved bronchodilation, health status and symptom
scores, and does not appear to be associated with
increased cardiovascular risk.64
Long-acting anticholinergic: Tiotropium bromide
Beneficial effects of treatment with tiotropium
on COPD exacerbations have been previously
demonstrated65---77 and have been confirmed more
recently in a study in which the number of exac-
erbations was the primary outcome. In a prospec-
tive, randomized, double blind, placebo-controlled,
parallel group study among 1829 patients with
moderate-to-severe stable COPD, Niewoehner and
colleagues showed that compared to placebo, six
months' treatment with tiotropium led to a longer
time to first exacerbation and hospitalization, fewer
overall exacerbations and exacerbation days, and
fewer days of antibiotics for COPD exacerbations,
as well as fewer unscheduled visits, hospitaliza-
tions and number of hospitalization days for COPD
exacerbation68. Interestingly, subgroup analysis did
not reveal any significant differences in the mag-
nitude of benefit (on exacerbations) when patients
were stratified according to age, current smoking
status, severity of airflow obstruction, hospitaliza-
tions, prednisone use or antibiotic use within the
past year, baseline inhaled steroid, LABA, theo-
phylline or home oxygen use. The favorable ef-
fect of tiotropium on exacerbation risk was evident
across all these patient groups. Beneficial treat-
ment effects of tiotropium on COPD exacerbations
with overall risk reduction of 20---25% have also
been demonstrated in a recent meta-analysis of
tiotropium therapy in COPD.69
Systemic corticosteroids
Although it is desirable to avoid systemic corticos-
teroids in the management of COPD whenever pos-
sible due the risk of adverse effects, systemic cor-
ticosteroids do play a role in prevention or relapse
of acute exacerbations, particularly if they result
in an emergency department (ED) visit or hospital-
ization. Aaron and colleagues showed that patients
with acute exacerbations of COPD treated in the ED
with bronchodilators and antibiotics who were also
discharged with a 10 day course of oral prednisone
40 mg/day had significantly longer time to subse-
quent exacerbation and lower relapse rates at 30
days as compared to patients treated in an identical
fashion in the ED but discharged on placebo (27% of
n = 74 vs. 43% of n = 73; p = 0.05).70
Inhaled corticosteroids
Although the use of inhaled corticosteroids (ICS)
in the management of patients with COPD remains
controversial, existing long-term, randomized clin-
ical trials have consistently shown that ICS can re-
duce exacerbation rates by approximately 20---30%.
Several well designed, randomized, controlled trials
have demonstrated a beneficial effect of inhaled ICS
on exacerbation prevention.71---74 The relative risk of
exacerbations following use of ICS (assessed in a to-
tal of 9 trials, including 3976 patients) was 0.7 (95%
CL 0.58---0.84) in a recent meta-analysis.75 Several
key observations regarding ICS and acute exacerba-
tions of COPD must, however, be noted. First, the
benefits of ICS do vary somewhat across trials. In
particular, there is less clear benefit of ICS on ex-
acerbations amongst those with very mild71 or very
severe72 airflow limitation. The majority of risk re-
duction has been evident amongst those trials where
study patients had had moderate-to-severe disease
(FEV1 ranging from 40---50% predicted). Importantly,
patients with significant bronchodilator reversibil-
ity (increase in FEV1 > 200 ml or more than 12%
increase in FEV1 post bronchodilator), even among
those with concurrent significant fixed airflow ob-
struction, have been excluded from participation in
these trials. Thus, the potential beneficial effects of
ICS on COPD exacerbations may have been underes-
timated by virtue of exclusion of patients with clear
COPD but with prominent ”asthmatic bronchitic fea-
tures”. Such patients likely have prominent airways
inflammation and bronchoconstriction in their COPD
phenotype and thus may be most likely to benefit
from ICS treatment. Also, most patients included in
these trials had fairly low baseline rates of exacer-
bation, whereas those with higher rates of exacer-
bations, persons unable to tolerate the medication
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wash-out phases of the studies or the most severe
disease were either not included or were difficult
to retain in the trials. Thus again, the effects of ICS
on reduction of exacerbation risk may have been un-
derestimated by existing data.
Another method of assessing the efficacy of
ICS in risk reduction for COPD exacerbations is to
ask the question: “what happens to patients cur-
rently taking ICS if the ICS are withdrawn from the
treatment regimen?” Two recent studies have ad-
dressed this question. In the COPE study, 244 pa-
tients with moderate COPD and a baseline exacer-
bation rate of 1.3 per year, taking fluticasone propi-
onate (FP) 1000 µg/day were randomized to either
continue FP for 6 months or take placebo during the
follow-up period. A higher proportion of patients
remaining on FP remained exacerbation-free com-
pared to those who had FP therapy withdrawn.76
Only 4.9% of patients taking FP, compared to 21.5%
of patients taking placebo developed rapid recur-
rent exacerbations (relative risk of exacerbation
4.4 among placebo group), and the placebo group
had a higher frequency of serious adverse events
including hospitalizations for acute exacerbations
than did the FP group. The findings of Wouters
and colleagues lend support to these results, by
demonstrating that withdrawal of inhaled FP from
a combination regimen of salmeterol/FP lead to in-
creased dyspnea, cough and sputum, increased ex-
acerbations and number of nights disturbed by res-
piratory symptoms, and fewer days without need
for rescue medication.77 Moreover, in an observa-
tional population-based cohort of patients within
the Canadian National Healthcare Service Database,
use of ICS (based on prescriptions issued) within
90 days following discharge from the hospital for a
diagnosis of COPD was associated with 24% fewer
readmissions for relapses and a 29% lower mortality
(even after adjustment for confounding factors)78
Thus, taken together, a strong evidence base sup-
ports the finding that use of ICS reduces the risk of
COPD exacerbations among patients with moderate-
to-severe degrees of airflow limitation.
Combination therapy with long-acting
beta-agonists and inhaled corticosteroids
Existing data suggest that therapy with a combina-
tion of LABA plus ICS appears to have the great-
est benefit in prevention of COPD exacerbations,
more than that seen with either agent alone. In the
TRISTAN Study, patients treated with combination
therapy had the greatest (25%) reduction in num-
ber of exacerbations per patient per year as com-
pared with those treated with salmeterol (20%) or
FP (19%) alone.79 All treatments reduced exacer-
bations compared with placebo. The treatment ef-
fect of combination therapy was greatest among
those patients with the most severe airflow obstruc-
tion (whose FEV1 was < 50% predicted), compared
to those with moderate degrees of airflow limita-
tion. Combination therapy also lead to a 39% re-
duction in the exacerbations requiring oral corticos-
teroid use, and to the greatest reductions in dysp-
nea and use of rescue medication use compared to
salmeterol or FP alone. In the recent TORCH study,
a randomized double-blind trial among 6112 COPD
patients, combination therapy with salmeterol/FP
reduced the annual rate of exacerbations from 1.13
to 0.85 and improved health status as well as pul-
monary function as compared with placebo.80 Stud-
ies have also evaluated the effects of combination
therapy with budesonide/formoterol as compared
with budesonide or formoterol alone, or placebo.
Overall the risk of severe exacerbation was reduced
by 24% among the combination therapy group in
both of these studies.81,82 Collectively, these data
suggest that combination therapy with ICS and LABA
has a greater protective effect with regard to ex-
acerbation prevention than does either class of
agent alone. Again, the exclusion of patients with
the most unstable symptoms (eg. those unable to
tolerate trial wash-out periods or who withdraw
from the study due to exacerbations) and those
with significant baseline bronchodilator reversibil-
ity from these trials may result in underestimation
of the potential benefits of combination therapy.
Limited data is available regarding the effects of
combination therapy with long-acting anticholiner-
gic and ICS, LABA plus tiotropium, or the combina-
tion of LABA, long-acting anticholinergic and ICS on
COPD exacerbations. Aaron and colleagues demon-
strated recently that addition of salmeterol/FP to
tiotropium therapy did not reduce the proportion
of patients who experienced an exacerbation in a
randomized, double-blind, placebo-controlled mul-
ticentre trial among 449 patients with moderate to
severe COPD.83 However, addition of salmeterol/FP
to tiotropium did lead to significant improvements
in lung function, HRQOL and importantly, reduced
the number of hospitalizations for COPD exacerba-
tion (incidence rate ratio 0.53) and all-cause hospi-
talizations. Further work is awaited in this area of
investigation.
Phosphodiesterase-4 inhibitors
Two recent studies suggest that in addition to bron-
chodilation, PDE-4 inhibitors have beneficial effects
on prevention of COPD exacerbations. Rabe and col-
leagues demonstrated that the PDE-4 inhibitor Rof-
lumilast was associated with a 34% reduction in the
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rate of exacerbations among patients with moder-
ate COPD.84 Similarly, in a trial evaluating the ef-
fects of the PDE-4 inhibitor Cilomilast among 647
patients with moderate-to-severe COPD, Cilomilast
therapy lead to a 39% reduction in risk of exacerba-
tion over the 6 month study period.85 Further work
is needed to discern the mechanisms by which PDE-4
inhibitors exert their beneficial effects on reducing
COPD exacerbations.
Mucolytic agents
Some patients with COPD experience regular spu-
tum production, and sputum production can in-
crease substantially during exacerbations, partic-
ularly those caused by airways infection. There-
fore, the effects of mucolytic agents (such as N-
acetylcysteine, NAC) on COPD exacerbations have
been assessed. In a retrospective analysis, oral NAC
reduced risk of re-hospitalization.86 Oral NAC also
reduced exacerbations in a 6 month randomized
trial among patients with COPD87, in a meta-analysis
among patients with chronic bronchitis88, and in
another systematic review89. However, a more re-
cent three year randomized trial of NAC vs. placebo
among COPD patients with a history of at least 2 ex-
acerbations per year for at least 2 years failed to
demonstrate any difference in number of exacerba-
tions per year or in rate of decline in lung function
over time90. Based on existing data, the routine use
of oral NAC is not recommended for patients with
COPD. However, given the apparent low risk of ad-
verse effects, oral NAC therapy might be considered
for patients with frequent recurrent exacerbations
despite regular use of the other pharmacotherapeu-
tic agents recommended in existing COPD manage-
ment guidelines.
Immunomodulators
The finding that only ∼15 to 20% of cigarette
smokers develop clinically significant COPD high-
lights the importance of individual host suscepti-
bility in the pathogenesis of the disease. It is also
likely that host susceptibility and immune compe-
tency (among other factors) impact the severity
of disease. Studies conducted to assess the ben-
efit of immuno-stimulatory agents such as OM-85-
BV (derived from bacterial extracts91), and AM3
(which improves phagocytic function of neutrophils
and macrophages, and improves function of natu-
ral killer T cells) in reducing risk of exacerbations
among patients with COPD show promising results.92
In the study by Collett and colleagues91, patients
treated with OM-85-BV had 55% fewer days in the
hospital for a respiratory problem and 30% lower risk
of having an exacerbation requiring hospitalization
as compared with patients treated with placebo,
although the overall risk of having at least one
episode of acute exacerbation did not differ be-
tween the two groups. This study suggested that
this immuno-modulator may reduce risk of more se-
vere (as opposed to all) respiratory events. How-
ever, a study among 253 patients with moderate
COPD evaluating the effects of 6 months' treatment
with AM3 did not demonstrate any difference com-
pared with placebo in frequency of exacerbations,
despite an improvement in patient-reported health
status as assessed by the SGRQ.93 Although the use
of immuno-modulatory agents to reduce exacerba-
tions of COPD is an intriguing concept, the relative
paucity of existing data is such that their routine
use cannot be recommended at this time. Further
studies are awaited.
Areas for future pharmacological interventions
Although significant gains have been made in recent
years in our understanding of the benefits of phar-
macologic therapy for patients with COPD, there
are many important areas wherein additional re-
search is needed. In order to more effectively re-
duce the risk and severity of COPD exacerbations
and the impact of these exacerbations on patients'
daily lives, we need further knowledge regarding
the mechanisms by which infections and other en-
vironmental agents trigger exacerbations. The role
of airway colonization by infectious pathogens and
the potential role of antibiotic therapy in reduc-
ing colonization must be assessed. Understanding
of the mechanisms by which individual classes of
medications reduce the risk of exacerbation is also
needed, to enable development of therapies that
may be even more effective than those available
currently. Evaluation of the effects of ICS, LABA
and combination therapies on exacerbation risk and
rate of decline in lung function among patients
with COPD with bronchodilator reversibility would
be of great interest. Investigation into the role of
newer combination therapies would also be use-
ful, as would studies to better understand how
to best utilize pharmacologic therapy in conjunc-
tion with non-pharmacologic interventions such as
PR and disease management programs. Additional
knowledge is also needed to address safety concerns
regarding the long term use of ICS (especially high
doses) and LABAs. Novel pharmacologic agents such
as anti-cytokine or anti-protease agents, as well
as agents that reduce leukocyte, bacterial or vi-
ral adherence or inhibit mucus secretion may prove
beneficial in preventing exacerbations and/or re-
tarding disease progression for some patients. Fi-
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nally, and of crucial importance, better understand-
ing is needed of the biological basis for the dif-
fering clinical phenotypes of COPD, so that ul-
timately, pharmacologic therapy can be individu-
ally tailored to both the patients most likely to
benefit from them, as well as avoid adverse out-
comes of therapies among patients less likely to de-
rive benefit. Lastly, combinations of pharmacolog-
ical and non-pharmacological studies can be stud-
ied. It is likely that optimal pharmacotherapy may
enhance the benefits of non-pharmacological inter-
ventions. Particularly the interaction of medication
and long acting bronchodilators has been studied in
this regard94, but other combinations may be worth-
while studying. For example the utilization of anti-
oxidants may have potential to enhance skeletal
muscle function after exacerbations95.
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